According to a new report, published by KBV research, The Global Multiomics Market size is expected to reach $5.7 billion by 2030, rising at a market growth of 15.0% CAGR during the forecast period.
The Single-cell Multiomics segment is showcasing a CAGR of 17.6% during (2023 - 2030). Developing single-cell RNA sequencing (scRNA-seq) and other single-cell technologies has significantly expanded the ability to capture individual cell profiles. These technologies have become more accessible, cost-effective, and scalable, making them attractive to researchers across disciplines. Single-cell multiomics techniques enable the integration of multiple omics layers, such as genomics, transcriptomics, and epigenomics, from the same individual cells. This comprehensive profiling provides a more holistic view of cellular function and regulation.
The Product segment gained the highest revenue in the Global Multiomics Market by Product & Service in 2022; thereby, achieving a market value of $3.5 billion by 2030. The continuous development and refinement of genomics, transcriptomics, proteomics, and metabolomics technologies have created more sophisticated and high-throughput instruments and reagents. Researchers require access to these advanced products to conduct their studies effectively. Governments, research institutions, and private organizations are allocating substantial funding to multiomics research projects.
The Pharmaceutical & Biotechnology Companies segment is registering a CAGR of 15.5% during (2023 - 2030). Multiomics data is instrumental in identifying potential drug targets. Genomics, transcriptomics, proteomics, and metabolomics provide insights into the molecular pathways and biological processes associated with diseases, enabling pharmaceutical and biotech companies to pinpoint specific genes, proteins, and metabolites as potential therapeutic targets. Omics data aids in the discovery of lead compounds by revealing the molecular mechanisms involved in disease progression.
The Genomics segment acquired the maximum revenue in the Global Multiomics Market by Platform in 2022; thereby, achieving a market value of $2.4 billion by 2030. Genomics has made significant inroads into clinical practice. Identifying disease-causing genetic mutations, developing diagnostic tests, and tailoring treatment plans based on a patient's genomic profile have become routine in healthcare. This has driven the integration of genomics into medical practice and has significantly contributed to its growth. Thus, there will be rising demand in the segment.
The Oncology segment is showcasing a CAGR of 15.5% during (2023 - 2030). Multiomics data has facilitated the discovery of critical driver mutations and molecular pathways in cancer. This has led to the development of targeted therapies that selectively inhibit the action of these specific molecular targets, minimizing damage to healthy cells and improving treatment efficacy. Examples include targeted therapies for HER2-positive breast cancer, BRAF-mutated melanoma, and EGFR-mutated non-small cell lung cancer (NSCLC). Therefore, the segment will expand rapidly in the coming years.
The North America region dominated the Global Multiomics Market by Region in 2022; and would continue to be a dominant market till 2030, thereby, achieving a market value of $2.6 billion by 2030. The Europe region is anticipated to grow at a CAGR of 14.6% during (2023 - 2030). Additionally, The Asia Pacific region would exhibit a CAGR of 16.2% during (2023 - 2030).
Full Report: https://www.kbvresearch.com/multiomics-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Thermo Fisher Scientific, Inc, Illumina, Inc., Danaher Corporation, PerkinElmer, Inc., Bruker Corporation, Qiagen N.V., Agilent Technologies, Inc., BGI Group, Becton, Dickinson, and Company, Shimadzu Corporation.
By Type
By Product & Service
By End-use
By Platform
By Application
By Geography
Companies Profiled
Unique Offerings 
